Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Moderate Buy” by Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $61.11.

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Piper Sandler increased their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a report on Wednesday.

Halozyme Therapeutics Stock Down 3.6 %

Shares of HALO stock opened at $46.84 on Thursday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The stock has a market cap of $5.96 billion, a PE ratio of 15.51, a price-to-earnings-growth ratio of 0.43 and a beta of 1.23. The business’s fifty day moving average is $51.20 and its 200-day moving average is $54.14. Halozyme Therapeutics has a 1 year low of $33.15 and a 1 year high of $65.53.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total value of $525,800.00. Following the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $35,583,199.52. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 30,000 shares of company stock valued at $1,621,800. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds have recently modified their holdings of HALO. International Assets Investment Management LLC bought a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $33,000. GAMMA Investing LLC increased its stake in Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $49,000. Toth Financial Advisory Corp bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $57,000. Finally, FSC Wealth Advisors LLC bought a new position in Halozyme Therapeutics in the third quarter worth $65,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.